CellSeed Inc. (JP:7776)
:7776
Top Page
CellSeed Inc.
(7776)
Select Model
Select Model
Rating:49Neutral
Price Target:
¥287.00
▲(10.81% Upside)
Action:ReiteratedDate:02/18/26
The score is primarily constrained by weak financial performance—sharp revenue deterioration, very large losses, and persistent cash burn—despite relatively low leverage. Technicals are supportive in the near term (price above key shorter moving averages with positive MACD), but valuation is hindered by negative earnings and no dividend data.
Positive Factors
Proprietary cell-sheet technology
CellSeed’s specialization in cell sheet engineering and tissue-regeneration creates a durable, high‑barrier niche in regenerative medicine. This proprietary focus supports long-term differentiation, specialized service revenues and potential durable partnerships if clinical/commercial progress continues.
Negative Factors
Sharp revenue deterioration
A 56.7% revenue decline materially reduces scale needed to absorb fixed costs and undermines commercialization momentum. Persistent top-line shrinkage over multiple quarters raises funding needs, weakens bargaining power with partners, and jeopardizes sustainable operations without reversing the trend.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary cell-sheet technology
CellSeed’s specialization in cell sheet engineering and tissue-regeneration creates a durable, high‑barrier niche in regenerative medicine. This proprietary focus supports long-term differentiation, specialized service revenues and potential durable partnerships if clinical/commercial progress continues.
Read all positive factors
CellSeed Inc. (7776) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥11.20B
Dividend YieldN/A
Average Volume (3M)621.90K
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth-42.49%
EPS Growth-2.37%
CountryJP
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-7.31
Shares Outstanding38,873,920
10 Day Avg. Volume981,780
30 Day Avg. Volume621,903
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)7.08
Price to Sales (P/S)107.39
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CellSeed Inc. Business Overview & Revenue Model
Company Description
CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated carti...
How the Company Makes Money
null...
CellSeed Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
57
Neutral
Cash Flow
16
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 83.68M | 193.28M | 190.13M | 126.43M | 161.67M |
| Gross Profit | 42.75M | 110.11M | 107.16M | 61.02M | 84.04M |
| EBITDA | -1.05B | -855.49M | -836.52M | -750.00M | -905.67M |
| Net Income | -1.10B | -859.84M | -846.53M | -759.68M | -912.87M |
Balance Sheet | |||||
| Total Assets | 1.66B | 2.43B | 2.47B | 1.54B | 1.41B |
| Cash, Cash Equivalents and Short-Term Investments | 1.32B | 2.13B | 2.16B | 1.07B | 846.67M |
| Total Debt | 132.92M | 143.75M | 151.25M | 158.75M | 160.00M |
| Total Liabilities | 387.46M | 269.88M | 301.05M | 365.58M | 363.58M |
| Stockholders Equity | 1.27B | 2.16B | 2.16B | 1.18B | 1.04B |
Cash Flow | |||||
| Free Cash Flow | -1.02B | -884.47M | -801.07M | -733.60M | -908.15M |
| Operating Cash Flow | -988.98M | -866.10M | -779.43M | -718.01M | -817.15M |
| Investing Cash Flow | -26.72M | -18.37M | 56.31M | 61.73M | -110.44M |
| Financing Cash Flow | 200.30M | 855.48M | 1.81B | 881.81M | 396.88M |
CellSeed Inc. Technical Analysis
Negative
259.00
Price Trends
317.74
Negative
311.85
Negative
390.78
Negative
Market Momentum
-9.28
Positive
42.02
Neutral
6.37
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7776, the sentiment is Negative. The current price of 259 is below the 20-day moving average (MA) of 311.50, below the 50-day MA of 317.74, and below the 200-day MA of 390.78, indicating a bearish trend. The MACD of -9.28 indicates Positive momentum. The RSI at 42.02 is Neutral, neither overbought nor oversold. The STOCH value of 6.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7776.
CellSeed Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | ¥16.36B | 120.78 | ― | ― | 1.24% | -33.41% | |
56 Neutral | ¥7.75B | 33.49 | ― | ― | 2.99% | -52.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥24.41B | -34.16 | ― | ― | -5.65% | -469.19% | |
50 Neutral | ¥50.09B | -13.30 | ― | ― | -82.33% | 47.73% | |
49 Neutral | ¥11.20B | -8.14 | ― | ― | -42.49% | -2.37% | |
45 Neutral | ¥18.99B | -11.30 | ― | ― | ― | 11.34% |
* Healthcare Sector Average
JP:7776
CellSeed Inc.
285.00
-182.00
-38.97%
JP:4593
Healios KK
344.00
122.00
54.95%
JP:4599
StemRIM Inc.
312.00
41.00
15.13%
JP:4978
ReproCELL Inc.
172.00
43.00
33.33%
JP:7096
StemCell Institute
753.00
-525.00
-41.08%
JP:7774
Japan Tissue Engineering Co., Ltd.
604.00
199.00
49.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.